Skip to main content
Premium Trial:

Request an Annual Quote

Caliper Collects $32.5M from Aclara on 2001 Settlement

SAN FRANCISCO, Oct. 15 - Caliper Technologies said today it received $32.5 million from Aclara Biosciences as part of a settlement from 2001 litigation.


Caliper will recognize $5 million of the payment as licensee fee revenue and $27.5 million as part of the settlement in its income statement, the company said.


Caliper said it will also receive a minimum of $2.5 million as royalty payments by December 31 of 2002 and 2003 under terms of the settlement.


In 2001, Caliper and Aclara settled lawsuits brought upon Aclara for infringing on lab-on-chip technology and Caliper for infringing on microfluidics methods. Previously, a jury granted Caliper $52 million in damages against Aclara for misappropriating its trade secrets, though this amount was reduced by a judge to $35 million.

The Scan

Drug Response Variants May Be Distinct in Somatic, Germline Samples

Based on variants from across 21 drug response genes, researchers in The Pharmacogenomics Journal suspect that tumor-only DNA sequences may miss drug response clues found in the germline.

Breast Cancer Risk Gene Candidates Found by Multi-Ancestry Low-Frequency Variant Analysis

Researchers narrowed in on new and known risk gene candidates with variant profiles for almost 83,500 individuals with breast cancer and 59,199 unaffected controls in Genome Medicine.

Health-Related Quality of Life Gets Boost After Microbiome-Based Treatment for Recurrent C. Diff

A secondary analysis of Phase 3 clinical trial data in JAMA Network Open suggests an investigational oral microbiome-based drug may lead to enhanced quality of life measures.

Study Follows Consequences of Early Confirmatory Trials for Accelerated Approval Indications

Time to traditional approval or withdrawal was shorter when confirmatory trials started prior to accelerated approval, though overall regulatory outcomes remained similar, a JAMA study finds.